Vivos Therapeutics Inc Total Assets
Vivos Therapeutics Inc total assets. Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) holds total assets worth $24.14 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Vivos Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Vivos Therapeutics Inc (2018–2025)
Total assets of Vivos Therapeutics Inc from 2018 to 2025. This chart illustrates how Vivos Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Vivos Therapeutics Inc stock price for real-time trading data and today's change.
Vivos Therapeutics Inc - Asset Composition Analysis
Vivos Therapeutics Inc Total Assets Breakdown (December 2025)
Vivos Therapeutics Inc total assets breakdown as of December 2025. Vivos Therapeutics Inc's total assets of $24.14 Million consist of 17.4% current assets and 82.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.1% |
| Accounts Receivable | $1.58 Million | 6.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.04 Million | 16.1% |
| Goodwill | $8.57 Million | 34.1% |
Asset Composition Trend (2018–2025)
This chart illustrates how Vivos Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Vivos Therapeutics Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vivos Therapeutics Inc's current assets represent 17.4% of total assets in 2025, a decrease from 24.5% in 2018.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2025, down from 15.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, a decrease from 58.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 34.1% of total assets.
Vivos Therapeutics Inc Competitors by Total Assets
Key competitors of Vivos Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Vivos Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.21 | 1.05 | 4.15 |
| Quick Ratio | 0.21 | 1.05 | 4.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-16.18 Million | $304.00K | $25.84 Million |
Vivos Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Vivos Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.86 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 64.6% |
| Total Assets | $25.15 Million |
| Market Capitalization | $2.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vivos Therapeutics Inc's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Vivos Therapeutics Inc's assets grew by 64.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vivos Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Vivos Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $25.15 Million | +64.56% |
| 2024-12-31 | $15.28 Million | +42.44% |
| 2023-12-31 | $10.73 Million | -21.79% |
| 2022-12-31 | $13.72 Million | -59.27% |
| 2021-12-31 | $33.69 Million | +33.01% |
| 2020-12-31 | $25.33 Million | +235.39% |
| 2019-12-31 | $7.55 Million | -7.95% |
| 2018-12-31 | $8.20 Million | -- |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnorma… Read more